Transcode Therapeutics (RNAZ) Retained Earnings (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Retained Earnings came in at $116.9 million in Q1 2026, up 255.27% YoY from $32.9 million in Q1 2025, and up 219.45% on a QoQ basis from -$97.9 million in Q4 2025.
Transcode Therapeutics (RNAZ) Retained Earnings (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Retained Earnings data on file, last reported at $116.9 million in Q1 2026.
- Quarterly Retained Earnings rose 255.27% year-over-year to $116.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $116.9 million (up 255.27% YoY) and the FY2025 annual result came in at -$97.9 million, down 259.95% from the prior year.
- Retained Earnings grew to $116.9 million in Q1 2026, from -$97.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $116.9 million in Q1 2026 to a low of -$97.9 million in Q4 2025.
- A 5-year average of -$10.3 million and a median of -$18.4 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings soared 312.08% — and 2025, when it slumped 259.95%.
- Tracing RNAZ's Retained Earnings over 5 years: stood at $31.1 million in 2022, then tumbled by 249.2% to -$46.4 million in 2023, then jumped by 231.81% to $61.2 million in 2024, then tumbled by 259.95% to -$97.9 million in 2025, then jumped by 219.45% to $116.9 million in 2026.
- The last three Retained Earnings figures came in at $116.9 million (Q1 2026), -$97.9 million (Q4 2025), and -$84.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | -122.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 116.90 Mn |
| Dec 31, 2025 | -97.86 Mn |
| Sep 30, 2025 | -84.42 Mn |
| Jun 30, 2025 | -79.56 Mn |
| Mar 31, 2025 | -75.29 Mn |
| Dec 31, 2024 | 61.18 Mn |
| Sep 30, 2024 | -57.26 Mn |
| Jun 30, 2024 | -54.90 Mn |
| Mar 31, 2024 | -49.74 Mn |
| Dec 31, 2023 | -46.42 Mn |
| Sep 30, 2023 | 46.77 Mn |
| Jun 30, 2023 | 39.12 Mn |
| Mar 31, 2023 | 32.45 Mn |
| Dec 31, 2022 | 31.11 Mn |
| Sep 30, 2022 | 30.98 Mn |
| Jun 30, 2022 | -18.45 Mn |
| Mar 31, 2022 | 30.77 Mn |
| Dec 31, 2021 | 30.71 Mn |
| Sep 30, 2021 | 30.67 Mn |
| Jun 30, 2021 | -5.18 Mn |